Last reviewed · How we verify

kanamycin/metronidazole — Competitive Intelligence Brief

kanamycin/metronidazole (kanamycin/metronidazole) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Aminoglycoside antibiotic, Antimicrobial agent. Area: Infectious disease.

phase 3 Aminoglycoside antibiotic, Antimicrobial agent 30S ribosomal subunit, DNA Infectious disease Small molecule Live · refreshed every 30 min

Target snapshot

kanamycin/metronidazole (kanamycin/metronidazole) — Japan Multinational Trial Organization. Kanamycin is an aminoglycoside antibiotic that inhibits protein synthesis by binding to the 30S ribosomal subunit, while metronidazole is an antimicrobial agent that kills bacteria by interfering with DNA replication.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
kanamycin/metronidazole TARGET kanamycin/metronidazole Japan Multinational Trial Organization phase 3 Aminoglycoside antibiotic, Antimicrobial agent 30S ribosomal subunit, DNA

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Aminoglycoside antibiotic, Antimicrobial agent class)

  1. Japan Multinational Trial Organization · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). kanamycin/metronidazole — Competitive Intelligence Brief. https://druglandscape.com/ci/kanamycin-metronidazole. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: